UNSPSC 51293014: Butriptyline hydrochloride

This classification denotes an antidepressant agent with the molecular formula C21H27N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LIJ2H8658W, chemically known as 5h-dibenzo(a,d)cycloheptene-5-propylamine, 10,11-dihydro-n,n,beta-trimethyl-, hydrochloride, dl- but more generally known as butriptyline hydrochloride, which bears US NIH Compound Identifier 21771. European Medicines Agency schedules Butriptyline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00922MIG.

UNSPSC 51293014 Butriptyline hydrochloride, a Commodity code, shows minimal direct relevance to recent state and local procurement activity. The three opportunities posted under this code—Seminole County's naloxone and drug deactivation systems procurement, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's (MMCAP) generic multi-source pharmaceuticals and OTC products RFP—are not specifically seeking amitriptyline hydrochloride or related tricyclic antidepressants. Rather, these solicitations reflect state and local government demand for naloxone and harm-reduction systems, direct-to-manufacturer pharmacy contracting models, and broad-based generic pharmaceutical supply through established wholesaler channels. The issuing bodies span state health and human services agencies (Texas HHS Commission), state purchasing cooperatives serving multiple jurisdictions (MMCAP, administered by Minnesota Department of Administration), and county health departments (Seminole County, Florida). None of these recent opportunities target the specific pharmaceutical product named in the code.

Geographic activity is concentrated in Texas, Minnesota (serving multiple participating states including Oregon), and Florida, with no evidence of solicitation activity specifically for butriptyline hydrochloride or other tricyclic antidepressants under this code. The three representative opportunities—Seminole County's IFB for naloxone (due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (response deadline April 3, 2026), and MMCAP's RFP for generic pharmaceuticals (due March 26, 2026)—indicate that state and local purchasing in this therapeutic area flows through broader pharmaceutical supply agreements, cooperative purchasing vehicles, and harm-reduction initiatives rather than through targeted procurements of individual antidepressant products. The code shows little actionable recent activity for firms specializing in this specific active pharmaceutical ingredient.